ILLUMINA ACCELERATOR

Illumina Accelerator Welcomes First Global Cohort of Genomics Startups

Retrieved on: 
Tuesday, June 23, 2020
Other Health, Pharmaceutical, Research, Baby, Maternity, Oncology, Software, Medical devices, Infectious diseases, Consumer, Genetics, Science, Technology, Clinical trials, Cardiology, Biotechnology, Agriculture, AIDS, Natural Resources, Health, Business incubators, DNA sequencing, Illumina, Inc., Microarrays, Startup accelerator, Startup company, Companies, Branches of biology, Biotechnology, Illumina Accelerator, Illumina

Illumina, Inc. (NASDAQ:ILMN) has selected seven early-stage companies to join the first global cohort of Illumina Accelerator, the company creation engine focused on partnering with entrepreneurs to build breakthrough genomics startups.

Key Points: 
  • Illumina, Inc. (NASDAQ:ILMN) has selected seven early-stage companies to join the first global cohort of Illumina Accelerator, the company creation engine focused on partnering with entrepreneurs to build breakthrough genomics startups.
  • As we navigate the current global pandemic, there is an even stronger urgency to create breakthrough genomics startups that will transform human health and beyond, said Amanda Cashin, Co-founder and Global Head of Illumina Accelerator.
  • Illumina Accelerator is the worlds first business accelerator focused solely on creating an innovation ecosystem for the genomics industry.
  • Since launching in 2014, Illumina Accelerator has invested in 45 genomics startups from across the globe, which have collectively raised approximately $400 million in venture capital funding.

Illumina Expands Genomics Accelerator to Cambridge, UK

Retrieved on: 
Tuesday, July 16, 2019
Consulting, Biotechnology, Professional services, Health, Medical devices, Research, Genetics, Science, DNA sequencing, Illumina, Inc., Microarrays, Mostafa Ronaghi, Startup accelerator, Illumina, Biology, Biotechnology, Life sciences, Illumina Accelerator, Illumina

Illumina Accelerator is proud to open its first international location at Illuminas Europe, Middle East and Africa (EMEA) headquarters in Cambridge, UK.

Key Points: 
  • Illumina Accelerator is proud to open its first international location at Illuminas Europe, Middle East and Africa (EMEA) headquarters in Cambridge, UK.
  • With the launch of Illumina Accelerator Cambridge, we are expertly positioned to further catalyze the rapidly expanding genomics ecosystem across EMEA.
  • In launching Illumina Accelerator Cambridge, we look forward to partnering with leading entrepreneurs and venture investors to harness the unique strengths and genomics expertise in the UK and beyond, said Mostafa Ronaghi, Ph.D., Illuminas Senior Vice President, Chief Technology Officer and Co-founder of Illumina Accelerator.
  • Illumina Accelerator is the worlds first business accelerator focused solely on creating an innovation ecosystem for the genomics industry.

Encoded Therapeutics, Inc. Announces $104 Million Series C Financing to Advance Lead Gene Therapy Program in Dravet Syndrome and Unveils its Precision Gene Therapy Platform

Retrieved on: 
Wednesday, June 26, 2019
Branches of biology, Biology, Life sciences, Emerging technologies, Epilepsy, Applied genetics, Medical genetics, Molecular biology, Dravet syndrome, Genetic disorder, Gene therapy, Illumina, Inc.

The Series C financing includes investments fromexisting shareholders Venrock, ARCH Venture Partners, Matrix Capital Management, Illumina Ventures, and Altitude Life Science Ventures.

Key Points: 
  • The Series C financing includes investments fromexisting shareholders Venrock, ARCH Venture Partners, Matrix Capital Management, Illumina Ventures, and Altitude Life Science Ventures.
  • Encoded will use the funds to advance its lead program in Dravet Syndrome and its preclinical pipeline, as well as to leverageits platform to develop new therapeutics to treat severe genetic disorders.
  • Encoded's approach to gene therapy may enable entirely new treatment paradigms for individuals with severe genetic disorders.
  • Our mission is to realize the potential of genomics-driven precision medicine by overcoming key limitations of viral gene therapy.